Stock listing

NASDAQ:ENGN enGene Therapeutics Inc. Stock

Home listing (NASDAQ) of enGene Therapeutics Inc.

Follow enGene Therapeutics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ENGN

$1.74 USD -0.11 (-5.9%)

Close on Nov 20, 2026

Past year -73.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.69 – $1.80 USDNov 20, 2026
Volume
556,716 sharesNov 20, 2026
Market cap
$116.6M USDAt the close on Nov 20, 2026 · price × 67.02M shares outstanding
52-week range
$1.40 – $12.25 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.08M USDMedian day 708,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
enGene Therapeutics Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ENGN · Home$1.74 USD-0.11 (-5.9%)556,716$1.75$1.80$1.685$1.85Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ENGN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.74-0.11-5.9%$1.75$1.80$1.685556,716
$1.85+0.13+7.6%$1.71$1.95$1.6542,805,866
$1.72-0.17-9.0%$1.89$1.95$1.6751,640,992
$1.89-0.52-21.6%$2.32$2.356$1.881,994,847
$2.41+0.13+5.7%$2.41$2.51$2.173,721,293
$2.28+0.48+26.7%$1.93$2.35$1.9011,909,681
$1.80+0.13+7.8%$1.70$1.81$1.632,765,800
$1.67-0.10-5.6%$1.76$1.76$1.63741,191
$1.77+0.02+1.1%$1.75$1.80$1.70848,998
$1.75+0.07+4.2%$1.68$1.775$1.6321,426,900
$1.68-0.04-2.3%$1.70$1.71$1.65624,200
$1.72+0.10+6.2%$1.585$1.75$1.5751,445,500
$1.62+0.17+11.7%$1.47$1.63$1.45937,100
$1.45-0.08-5.2%$1.55$1.55$1.45587,200
$1.530.000.0%$1.53$1.55$1.461,197,800
$1.53-0.05-3.2%$1.57$1.62$1.52690,400
$1.58+0.03+1.9%$1.54$1.60$1.535997,400
$1.55-0.03-1.9%$1.625$1.625$1.55365,300
$1.58+0.02+1.3%$1.57$1.625$1.554657,800
$1.56-0.02-1.3%$1.55$1.575$1.54730,200
$1.58-0.05-3.1%$1.619$1.65$1.57554,600
$1.63-0.04-2.4%$1.68$1.681$1.591,108,900
$1.67+0.09+5.7%$1.60$1.72$1.591,119,600
$1.58-0.09-5.4%$1.66$1.70$1.58782,000
$1.67-0.04-2.3%$1.73$1.749$1.651,156,500
$1.71+0.15+9.6%$1.61$1.735$1.581,176,800
$1.56-0.07-4.3%$1.60$1.62$1.56943,500
$1.63-0.07-4.1%$1.69$1.70$1.62913,800
$1.70-0.03-1.7%$1.73$1.74$1.69462,700
$1.73-0.05-2.8%$1.76$1.81$1.72359,100
$1.78+0.035+2.0%$1.75$1.79$1.681,460,600
$1.745-0.055-3.1%$1.80$1.859$1.74708,300
$1.80-0.07-3.7%$1.87$1.87$1.80361,700
$1.87-0.07-3.6%$1.94$1.94$1.785952,900
$1.94-0.04-2.0%$2.00$2.02$1.93690,100
$1.98-0.02-1.0%$2.01$2.01$1.96903,000
$2.00+0.05+2.6%$1.965$2.02$1.931,280,600
$1.95-0.02-1.0%$1.97$1.97$1.915393,200
$1.97+0.01+0.5%$1.96$1.98$1.90332,200
$1.96+0.04+2.1%$1.94$1.969$1.8751,976,100
$1.92-0.08-4.0%$1.99$1.99$1.905796,300
$2.00-0.05-2.4%$2.05$2.05$1.98669,000
$2.05+0.09+4.6%$1.96$2.08$1.961,063,800
$1.96+0.05+2.6%$1.92$1.97$1.90426,300
$1.910.000.0%$1.92$1.93$1.89401,000
$1.910.000.0%$1.90$1.92$1.88637,500
$1.91+0.02+1.1%$1.90$1.915$1.88579,300
$1.89+0.02+1.1%$1.87$1.90$1.845618,700
$1.87+0.07+3.9%$1.80$1.88$1.80460,500
$1.80+0.03+1.7%$1.80$1.83$1.79651,000
$1.77-0.08-4.3%$1.85$1.85$1.76565,300
$1.85-0.07-3.6%$1.89$1.92$1.84486,400
$1.92+0.10+5.5%$1.82$1.94$1.781,508,300
$1.82-0.01-0.5%$1.82$1.835$1.78412,700
$1.83-0.06-3.2%$1.90$1.91$1.80634,500
$1.89+0.035+1.9%$1.84$1.919$1.8351,061,700
$1.855+0.015+0.8%$1.84$1.87$1.80657,400
$1.84+0.015+0.8%$1.83$1.855$1.81291,300
$1.825-0.085-4.5%$1.91$1.91$1.81447,100
$1.91-0.04-2.1%$1.94$1.94$1.91252,100
$1.95+0.08+4.3%$1.87$1.95$1.871,826,600
$1.87+0.06+3.3%$1.82$1.886$1.8151,005,400
$1.81+0.03+1.7%$1.79$1.83$1.75641,900
$1.78+0.01+0.6%$1.795$1.805$1.77242,700
$1.77-0.08-4.3%$1.84$1.85$1.755368,400
Ticker
NASDAQ:ENGN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All enGene Therapeutics Inc. news

enGene Therapeutics Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
17 in the last 12 months · 61 in all · newest Nov 11, 2026 · oldest 2023
Decks
16 decks · latest Nov 12, 2026

Where enGene Therapeutics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ENGN · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ENGNBOATSUnited StatesUSD
Frankfurt:S0N0FrankfurtGermanyEUR

Valuation

Price/book 0.5× against a median of 2.6×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Jul 31, 2026 · price Nov 20, 2026

Enterprise value
−$149.7M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.5×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.82

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
enGene Therapeutics Inc. · NASDAQ:ENGNUS$116.6M−US$149.7Mn/an/an/a0.5×n/a0.0×1.82
Alar Pharmaceuticals Inc · TPEX:6785US$121.0MUS$51.68Mn/a568×n/a1.7×n/a0.0×n/a
CANbridge Pharmaceuticals Inc. · HKEX:1228US$120.4MUS$111.5Mn/a13.3×n/an/a−146.4%n/an/a
Atrium Therapeutics, Inc. · NASDAQ:RNAUS$118.4M−US$113.0Mn/a−2.9×n/a0.6×−229.7%0.0×0.76
Adagene, Inc. · NASDAQ:ADAGUS$118.2M−US$3.65Mn/a−0.5×n/a1.1×−229.6%0.1×1.43
STCube, Inc. · KRX:052020US$117.7MUS$72.02Mn/a13.6×n/a2.6×−338.7%0.0×n/a
PegBio Co., Ltd. Class H · HKEX:2565US$117.2MUS$55.83Mn/an/an/a2.9×n/a0.0×n/a
Curacle Co., Ltd. · KRX:365270US$116.9MUS$99.85Mn/a16.3×n/a3.4×−92.1%0.0×n/a
Sinew Pharma, Inc. · TPEX:6634US$114.4MUS$84.23Mn/a59,068×n/a3.6×n/a0.0×n/a
Armata Pharmaceuticals, Inc. · AMEX:ARMPUS$112.7MUS$346.0Mn/a45.8×n/an/an/an/a0.97
Medigen Biotechnology Corporation · TPEX:3176US$111.8MUS$61.96Mn/a1.6×n/a2.5×−19.9%0.8×n/a
Median of the othersUS$117.4MUS$66.99M13.6×2.6×−188.0%0.0×0.97

Forecasts

4 strong buy · 2 buy · 3 hold · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
4.29 USD · Analysts' mean
EPS, year to Oct 2026
-1.82 · 8 analysts

Team and board

Officers

OfficerRole
Ron CooperChief Executive Officer

Board

DirectorRole
Michael HeffernanChairman
Ron CooperChief Executive Officer
William GrossmanDirector

Events

Next results
Dec 28, 2026 (expected)
QuarterResultsShare move
Q3 2026Sep 8, 2026 · Before open+5.5%
Q2 2026Jun 15, 2026 · Before open+9.3%
Q1 2026Mar 9, 2026−20.1%
Q4 2025Dec 22, 2025 · After close+5.1%
Q3 2025Sep 11, 2025 · After close−5.8%
Q2 2025Jun 12, 2025 · Before open+0.9%
Q1 2025Mar 10, 2025 · After close−1.7%
Q4 2024Dec 19, 2024 · After close−2.2%
Q3 2024Sep 10, 2024 · After close+3.1%
Q2 2024Jun 14, 2024 · Before open−10.0%
All 19 quarters
QuarterResultsShare move
Q1 2024Mar 11, 2024 · After close+1.6%
Q4 2023Jan 3, 2024−22.3%
Q2 2023Jun 30, 2023+0.1%
Q1 2023Mar 30, 2023+0.6%
Quarter to Oct 31, 2022Nov 10, 2022+0.4%
Quarter to Jul 31, 2022Aug 11, 2022−0.2%
Quarter to Apr 30, 2022May 13, 2022−0.8%
Quarter to Jan 31, 2022Apr 14, 2022−0.1%
Quarter to Oct 31, 2021Jan 24, 2022

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck41 slidesNov 12, 2026
Technical Presentation (November 2026)Technical35 slidesNov 12, 2026
Technical Presentation (October 2026)Technical35 slidesOct 15, 2026
Investor Presentation (September 2026)Investor deck37 slidesSeptember 2026
Investor Day (August 2026)Investor day23 slidesAug 11, 2026
Investor Presentation (July 2026)Investor deck35 slidesJul 17, 2026
Corporate Update (May 2026)Corporate update20 slidesMay 7, 2026
American Urological Association Annual Meeting 2026Conference12 slidesMay 2026
Investor Presentation (November 2025)Investor deck31 slidesNov 12, 2025
Corporate Update (November 2025)Corporate update15 slidesNov 12, 2025
All 16 decks
DeckKindSlidesDate
Investor Presentation (September 2025)Investor deck28 slidesSep 3, 2025
Investor Presentation (October 2024)Investor deck28 slidesOct 25, 2024
Technical Presentation (September 2024)Technical7 slidesSep 26, 2024
Investor Presentation (September 2024)Investor deck25 slidesSep 5, 2024
Investor Presentation (June 2024)Investor deck21 slidesJun 14, 2024
2024 AUA Annual MeetingConference12 slides2024

Open Decks

Financings

RaiseDate
Public offering of common shares
Announced: Jefferies +2
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), Wells Fargo Securities (co-lead)
Nov 12, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Research and development94.5M38.3M16.5M15.5M
Operating income-123.2M-62.3M-26.1M-19.4M
Depreciation and amortization500.0K300.0K200.0K200.0K
EBITDA-122.7M-62.0M-25.9M-19.2M
Interest expense2.99M2.80M4.95M1.42M
Income before tax-117.3M-55.2M-99.9M-24.4M
Income tax0-19.0K17.0K22.0K
Net income-117.3M-55.1M-99.9M-24.5M
Earnings per share, basic2.291.46151.2244.30
Earnings per share, diluted2.291.46151.2244.30

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents50.2M173.0M81.5M20.4M
Short-term investments143.6M65.3M
Current assets201.4M247.4M85.4M22.6M
Property, plant and equipment2.48M1.17M589.0K387.0K
Total assets221.5M311.2M87.0M23.9M
Accounts payable6.69M1.41M1.16M723.0K
Current liabilities32.0M14.7M5.26M5.10M
Total liabilities53.8M38.6M14.5M47.4M
Shareholders' equity167.7M272.6M72.5M-76.6M
Shares outstanding52.0M51.0M23.2M665.8K

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-99.2M-48.3M-24.7M-17.6M
Capital spending-1.49M-925.0K-318.0K-153.0K
Free cash flow-100.7M-49.2M-25.1M-17.7M
Cash from investing-25.1M-126.0M-318.0K-153.0K
Cash from financing1.52M265.7M86.1M28.0M
Dividends paid0
Change in cash-122.9M91.5M61.1M9.42M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
3 · Initial statement of ownershipNov 13, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
8-K · Current reportNov 12, 2026ResultsSEC
4 · Change in ownershipSep 24, 2026Insider tradeSEC
10-Q · Quarterly reportSep 8, 2026Quarterly reportSEC
8-K · Current reportSep 8, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2026Big-stake noticeSEC
8-K · Current reportAug 11, 2026Current reportSEC
3 · Initial statement of ownershipJul 22, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 22, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 22, 2026Big-stake noticeSEC
8-K · Current reportJul 17, 2026Current reportSEC
8-K · Current reportJul 16, 2026Management or board changeSEC
8-K/A · Current report, amendedJun 18, 2026Management or board changeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
10-Q · Quarterly reportJun 15, 2026Quarterly reportSEC
8-K · Current reportJun 15, 2026ResultsSEC
8-K · Current reportJun 10, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 13, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersMay 8, 2026Annual reportSEC
DEF 14A · Proxy statementMay 8, 2026Meeting noticeSEC
8-K · Current reportMay 7, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 5, 2026Big-stake noticeSEC
8-K · Current reportApr 9, 2026Current reportSEC
S-8 · Registration statement for employee plansMar 9, 2026Offer documentSEC
424B5 · ProspectusMar 9, 2026Offer documentSEC
8-K · Current reportMar 9, 2026Material contractSEC
10-Q · Quarterly reportMar 9, 2026Quarterly reportSEC
8-K · Current reportMar 9, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveMar 3, 2026Other filingsSEC
CORRESP · Letter to the SECFeb 26, 2026Other filingsSEC
UPLOAD · Letter from the SECFeb 25, 2026Other filingsSEC
S-3 · Registration statementFeb 19, 2026Offer documentSEC
10-K/A · Annual report, amendedFeb 19, 2026Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 27, 2026Big-stake noticeSEC
8-K · Current reportJan 21, 2026Material contractSEC
8-K · Current reportJan 21, 2026Current reportSEC
10-K · Annual reportDec 22, 2025Annual reportSEC
8-K · Current reportDec 22, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 18, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 18, 2025Big-stake noticeSEC
8-K · Current reportNov 14, 2025Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
424B5 · ProspectusNov 14, 2025Offer documentSEC
424B5 · ProspectusNov 12, 2025Offer documentSEC
8-K · Current reportNov 12, 2025Current reportSEC
8-K · Current reportOct 2, 2025Management or board changeSEC
8-K/A · Current report, amendedOct 2, 2025Management or board changeSEC
4 · Change in ownershipOct 1, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 1, 2025Insider tradeSEC
8-K · Current reportSep 30, 2025Current reportSEC
S-8 · Registration statement for employee plansSep 11, 2025Offer documentSEC
10-Q · Quarterly reportSep 11, 2025Quarterly reportSEC
8-K · Current reportSep 11, 2025ResultsSEC
8-K · Current reportSep 3, 2025Current reportSEC
4 · Change in ownershipJul 14, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 14, 2025Insider tradeSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 8, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 8, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 8, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 8, 2025Insider tradeSEC
8-K · Current reportJul 8, 2025Management or board changeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
4 · Change in ownershipJun 16, 2025Insider tradeSEC
10-Q · Quarterly reportJun 12, 2025Quarterly reportSEC
8-K · Current reportJun 12, 2025ResultsSEC
8-K · Current reportJun 10, 2025Management or board changeSEC
8-K · Current reportJun 9, 2025Material contractSEC
8-K · Current reportJun 4, 2025Management or board changeSEC
3 · Initial statement of ownershipMay 29, 2025Insider tradeSEC
ARS · Annual report to shareholdersMay 9, 2025Annual reportSEC
DEF 14A · Proxy statementMay 9, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 10, 2025Offer documentSEC
10-Q · Quarterly reportMar 10, 2025Quarterly reportSEC
8-K · Current reportMar 10, 2025ResultsSEC
10-K/A · Annual report, amendedFeb 20, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 29, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 29, 2025Big-stake noticeSEC
8-K · Current reportDec 20, 2024Material contractSEC
424B5 · ProspectusDec 20, 2024Offer documentSEC
10-K · Annual reportDec 19, 2024Annual reportSEC
8-K · Current reportDec 19, 2024ResultsSEC
EFFECT · Notice that a registration is effectiveNov 22, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveNov 22, 2024Other filingsSEC
424B3 · ProspectusNov 21, 2024Offer documentSEC
424B3 · ProspectusNov 21, 2024Offer documentSEC
CORRESP · Letter to the SECNov 19, 2024Other filingsSEC
CORRESP · Letter to the SECNov 19, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 18, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 18, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
S-3 · Registration statementNov 13, 2024Offer documentSEC
S-3 · Registration statementNov 13, 2024Offer documentSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
4 · Change in ownershipNov 1, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedNov 1, 2024Big-stake noticeSEC
424B3 · ProspectusOct 28, 2024Offer documentSEC
8-K · Current reportOct 25, 2024Material contractSEC
4 · Change in ownershipOct 22, 2024Insider tradeSEC
4 · Change in ownershipOct 22, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2024Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 21, 2024Big-stake noticeSEC
424B3 · ProspectusOct 21, 2024Offer documentSEC
8-K · Current reportOct 21, 2024Management or board changeSEC
SC 13D/A · Big-stake notice, amendedOct 18, 2024Big-stake noticeSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
4 · Change in ownershipOct 1, 2024Insider tradeSEC
424B3 · ProspectusSep 26, 2024Offer documentSEC
8-K · Current reportSep 26, 2024Current reportSEC
424B3 · ProspectusSep 10, 2024Offer documentSEC
10-Q · Quarterly reportSep 10, 2024Quarterly reportSEC
8-K · Current reportSep 10, 2024ResultsSEC
8-K · Current reportSep 5, 2024Current reportSEC
4 · Change in ownershipJul 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 25, 2024Insider tradeSEC
4 · Change in ownershipJul 24, 2024Insider tradeSEC
3 · Initial statement of ownershipJul 24, 2024Insider tradeSEC
424B3 · ProspectusJul 24, 2024Offer documentSEC
8-K · Current reportJul 24, 2024Management or board changeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC
424B3 · ProspectusJun 14, 2024Offer documentSEC
10-Q · Quarterly reportJun 14, 2024Quarterly reportSEC
8-K · Current reportJun 14, 2024ResultsSEC
4 · Change in ownershipMay 29, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 17, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 17, 2024Insider tradeSEC
424B3 · ProspectusMay 15, 2024Offer documentSEC
8-K · Current reportMay 15, 2024Management or board changeSEC
424B3 · ProspectusApr 25, 2024Offer documentSEC
4 · Change in ownershipApr 22, 2024Insider tradeSEC
ARS · Annual report to shareholdersApr 18, 2024Annual reportSEC
DEF 14A · Proxy statementApr 18, 2024Meeting noticeSEC
4 · Change in ownershipMar 25, 2024Insider tradeSEC
4 · Change in ownershipMar 20, 2024Insider tradeSEC
4 · Change in ownershipMar 19, 2024Insider tradeSEC
424B3 · ProspectusMar 11, 2024Offer documentSEC
10-Q · Quarterly reportMar 11, 2024Quarterly reportSEC
8-K · Current reportMar 11, 2024ResultsSEC
EFFECT · Notice that a registration is effectiveMar 6, 2024Other filingsSEC
424B3 · ProspectusMar 5, 2024Offer documentSEC
CORRESP · Letter to the SECMar 4, 2024Other filingsSEC
S-8 · Registration statement for employee plansFeb 26, 2024Offer documentSEC
CORRESP · Letter to the SECFeb 26, 2024Other filingsSEC
S-1/A · Registration statement, amendedFeb 26, 2024Offer documentSEC
SC 13G · Big-stake noticeFeb 26, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 23, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 23, 2024Big-stake noticeSEC

This page holds 200 of 272 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from enGene Therapeutics Inc.’s releases · as of Nov 12, 2025

Common shares
67,016,316
Fully diluted
67,466,316

Fully diluted

LineShares
Common shares67,016,316
Options and RSUs450,000

Warrants and options

Lot
Stock options · expiry not stated

Share count over time

CountShares
Nov 22, 202667,016,316

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Lota S Zoth
Other companies: First Financial Bankshares, Inc. (Director · Since at least Apr 28, 2026); 89bio Inc (Director · Since at least Jun 1, 2020); Inovio Pharmaceuticals, Inc. (Director · Since at least Jan 3, 2019); Zymeworks Inc. (Director · Jan 1, 2019 – Dec 21, 2022 · Past); Spark Therapeutics Inc (CHIEF SCIENTIFIC OFFICER, Director · Jan 6, 2016 – Dec 17, 2019 · Past); Lumos Pharma Inc (Director · Nov 2, 2012 – Dec 12, 2024 · Past); Hyperion Therapeutics Inc (Director · Jul 25, 2012 – May 7, 2015 · Past); Orexigen Therapeutics Inc (Director · Apr 26, 2012 – Jul 14, 2017 · Past); Medimmune Inc (SVP, Chief Financial Officer · Feb 23, 2006 – Jun 18, 2007 · Past)
Director · Since at least Dec 18, 2023
Michael Heffernan
Other companies: Avalo Therapeutics, Inc. (Chairman of the Board · Since at least Mar 25, 2025); Biohaven Ltd. (Director · Since at least Sep 28, 2022); Trevi Therapeutics, Inc. (Lead Independent Director · Since at least May 7, 2019); Synlogic Inc (Director · Dec 8, 2020 – Jun 22, 2023 · Past); Biohaven Pharmaceutical Holding Co Ltd (Director · Jan 31, 2020 – Oct 3, 2022 · Past); Akebia Therapeutics, Inc. (Director · Dec 12, 2018 – Jun 2, 2021 · Past); Keryx Biopharmaceuticals Inc (Director · Jun 21, 2016 – Dec 12, 2018 · Past); Collegium Pharmaceutical, Inc. (Director · May 6, 2015 – Feb 10, 2025 · Past); Ocata Therapeutics Inc (Director · Apr 11, 2012 – Feb 10, 2016 · Past)
Director · Since at least Jul 8, 2025
Paul Hastings
Other companies: Nkarta, Inc. (CHIEF EXECUTIVE OFFICER · Since at least Jul 9, 2020); Protara Therapeutics, Inc. (Director · Oct 18, 2016 – Jun 8, 2018 · Past); Relypsa Inc (Director · Nov 14, 2013 – Sep 1, 2016 · Past); OncoMed Pharmaceuticals Inc (Chairman & CEO · Jul 17, 2013 – Oct 10, 2017 · Past); Pacira BioSciences, Inc. (Director · Jun 2, 2011 – Jun 12, 2024 · Past)
Director · Since at least May 15, 2024
Ron Cooper
Other companies: C4 Therapeutics, Inc. (Director · Since at least Jun 7, 2024); Generation Bio Co (Director · Since at least Mar 1, 2021); Albireo Pharma Inc (President and CEO, Director · Nov 3, 2016 – Mar 2, 2023 · Past)
Chief Executive Officer · Since at least Jul 22, 2024
William Grossman
Other companies: Day One Biopharmaceuticals Inc (Director · Since at least Jan 17, 2024); Arcus Biosciences, Inc. (Chief Medical Officer · Apr 29, 2019 – Jun 16, 2021 · Past); Bellicum Pharmaceuticals Inc (Sr. VP, Chief Medical Officer · Feb 5, 2018 – Feb 5, 2019 · Past)
Director · Since at least Jul 8, 2025
Constantine Chinoporos
Other companies: Geron Corporation (Director · Since at least Mar 25, 2026); Applied Therapeutics Inc (See Remarks · Since at least Dec 28, 2023)
Interim Chief Business Officer · Since at least Jul 16, 2026
Philip Astley-Sparke
Other companies: Replimune Group, Inc. (Director · Since at least Jul 19, 2018); uniQure N.V. (Director · Jan 26, 2018 – Mar 2, 2021 · Past)
Director · Since at least Jul 8, 2025
Richard Paul Bryce
Other companies: Rain Oncology Inc (Chief Medical Officer · Apr 22, 2021 – Feb 15, 2023 · Past); Puma Biotechnology Inc (SEE REMARKS · Jun 20, 2012 – Apr 5, 2021 · Past)
Chief Medical Officer · Oct 31, 2023 – Nov 30, 2023 · Past
Wouter Joustra
Other companies: Vor Biopharma Inc. (Director · Since at least Dec 18, 2025); NewAmsterdam Pharma Company N.V. (Director · Jul 16, 2024 – Jul 16, 2024 · Past)
Director · Since at least May 15, 2024
Amy Pott
Other companies: Wave Life Sciences Ltd. (Director · Sep 4, 2019 – Aug 18, 2020 · Past)
Chief Global Comm. Ofc. · Since at least May 27, 2025
All 26 people
PersonSeat
D Ryan Daws
Other companies: Concert Pharmaceuticals Inc (Chief Financial Officer · Feb 12, 2014 – Jan 4, 2017 · Past)
Chief Financial Officer · Since at least Nov 27, 2023
Gerald A Brunk
Other companies: LAVA Medtech Acquisition Corp (President, Director · Oct 26, 2021 – Oct 26, 2021 · Past)
Director · Since at least Oct 31, 2023
Jason David Hanson
Other companies: BullFrog AI Holdings, Inc. (Director · Since at least Feb 13, 2023)
Chief Executive Officer, Director · Oct 31, 2023 – Oct 31, 2023 · Past
Jasper Bos
Other companies: Braveheart Bio, Inc. (Director · Since at least Aug 5, 2026)
Director · Since at least Oct 31, 2023
Jill Buck
Other companies: Alaunos Therapeutics, Inc. (EVP, GM Gene Therapy · Jun 13, 2019 – Mar 4, 2021 · Past)
Chief Development Officer · Since at least Jul 8, 2025
Lee Giguere
Other companies: Chiasma Inc (General Counsel · Dec 5, 2019 – Aug 5, 2021 · Past)
Chief Legal Ofc. and Corp Secy · Since at least Jan 29, 2024
Richard Glickman
Other companies: ESSA Pharma Inc (Director · Since at least Oct 1, 2020)
Director · Since at least Oct 31, 2023
Alexander Julian NicholsChief Strategy & Ops. Ofc · Since at least Oct 31, 2023
Alexandre Jean-Rene Erwan GrassinInt. Chief Financial Officer · Oct 31, 2023 – Oct 31, 2023 · Past
Anthony Tzeyew CheungChief Scientific Officer · Since at least Oct 31, 2023
Hussein SweitiChief Medical Officer · Since at least Sep 29, 2025
James Crowley SullivanChief Scientific Officer · Oct 31, 2023 – Oct 31, 2023 · Past
Joan ConnollyChief Technology Officer · Since at least Oct 21, 2024
Kathleen P RichtonSVP, Finance and Treasurer · Since at least Jul 16, 2026
Matthew Ross BoydChief Regulatory Officer · Since at least Jul 8, 2025
Raj Som PruthiChief Medical Officer · Jul 22, 2024 – Jan 29, 2025 · Past

Open People

Log in to ask 6ix AI your own questions about enGene Therapeutics Inc.